Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
19/05/2026 12:36
May 19 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA ANNOUNCES SUCCESSFUL OUTCOME OF FDA TYPE C MEETING REQUEST FOR HARMONIC™ PHASE 2 TRIAL OF LP-300 IN NEVER-SMOKERS WITH NSCLC LANTERN PHARMA INC - FDA RAISES NO OBJECTIONS TO KEY PROPOSED HARMONIC TRIAL AMENDMENTS LANTERN PHARMA INC - HARMONIC TRIAL TO FOCUS ENROLLMENT ON EGFR EXON 21 L858R MUTATION PATIENTS LANTERN PHARMA INC - HARMONIC TRIAL TO INCREASE MAXIMUM LP-300 TREATMENT CYCLES TO EIGHT LANTERN PHARMA INC - HARMONIC TRIAL TO DISCONTINUE CONTROL ARM OF THE HARMONIC TRIAL AND MIGRATE TO SINGLE-ARM DESIGN Source text: ID:nBwkdPPla Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments